BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16943524)

  • 1. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
    Uchida K; Danenberg PV; Danenberg KD; Grem JL
    BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
    O'Neil BH; McLeod HL
    J Clin Oncol; 2006 Sep; 24(25):4051-3. PubMed ID: 16943521
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
    Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
    Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
    Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
    Yanagisawa Y; Maruta F; Iinuma N; Ishizone S; Koide N; Nakayama J; Miyagawa S
    Scand J Gastroenterol; 2007 Apr; 42(4):477-84. PubMed ID: 17454858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
    Lassmann S; Hennig M; Rosenberg R; Nährig J; Schreglmann J; Krause F; Poignee-Heger M; Nekarda H; Höfler H; Werner M
    Int J Colorectal Dis; 2006 Apr; 21(3):238-47. PubMed ID: 16132996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
    Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
    Petrioli R; Bargagli G; Lazzi S; Pascucci A; Francini E; Bellan C; Conca R; Martellucci I; Fiaschi AI; Lorenzi B; Francini G;
    Anticancer Drugs; 2010 Mar; 21(3):313-9. PubMed ID: 20016369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
    J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
    Bai W; Wu Y; Zhang P; Xi Y
    Int J Clin Exp Pathol; 2015; 8(10):12333-45. PubMed ID: 26722420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.
    Noda E; Maeda K; Inoue T; Nishihara T; Nishiguchi Y; Ohira M; Hirakawa K
    Anticancer Res; 2006; 26(6C):4653-8. PubMed ID: 17214322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
    Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
    Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Renouf DJ; Welch S; Moore MJ; Krzyzanowska MK; Knox J; Feld R; Liu G; MacKay H; Petronis J; Wang L; Chen E
    Cancer Chemother Pharmacol; 2012 May; 69(5):1339-44. PubMed ID: 22349811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.